Journals / Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi / 2019 / Cilt: 24 - Sayı: 2

The Effect of Infusion Speed on Nephrotoxicity in Patients Receiving Colistine Treatment in Oncology Hospital

Onkoloji Hastanesinde Kolistin Tedavisi Verilen Hastalarda İnfüzyon Hızının Nefrotoksisite Üzerine Etkisi

Pages
87–92
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Further studies are needed to support the present study.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: Infections with multi-resistant gram-negative bacteria have recently become a major problem, and colistin is one of the best alternatives for patients who cannot be treated using broad-spectrum antibiotics.
📊
Key Findings & Data:Colistin was administered through IV push (rapid infusion) to 52 patients, and through slow infusion to 38 patients.
💡
Conclusion & Impact:Further studies are needed to support the present study.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Introduction: Infections with multi-resistant gram-negative bacteria have recently become a major problem, and colistin is one of the best alternatives for patients who cannot be treated using broad-spectrum antibiotics. However, colistin has many side effects including nephrotoxicity. Colistin can be administered as long or short infusions according to its pharmacokinetic/pharmacodynamic properties. In the present study, it was aimed to investigate the effect of mode of colistin administration on nephrotoxicity in patients in the intensive care unit. Materials and Methods: Ninety patients were included into the study. Colistin was administered through IV push (rapid infusion) to 52 patients, and through slow infusion to 38 patients. Demographic properties and acute renal failure (ARF) parameters of colistin-administered patients were recorded. Results: The characteristics of the disease and ages of the two groups were similar. ARF was less frequent in the slow colistin infusion group (p< 0.011). Conclusion: Administration of colistin in the treatment of infections with multidrug-resistant microorganisms should be performed through long infusion method to avoid the nephrotoxic side effect of colistin. Further studies are needed to support the present study.

Özet

Çoklu dirençli gram-negatif bakterilerle oluşan infeksiyonlar günümüzde önemli bir sorun olup, geniş spektrumlu antibiyotiklerle tedavi edilemeyen hastalar için kolistin en etkili seçenek olarak görünmektedir. Kolistin, nefrotoksisite başta olmak üzere bir çok yan etkiye sahiptir. Farmakokinetik/farmakodinamik (FK/FD) özelliklerine göre uzun infüzyon ya da kısa infüzyonla verilebilmektedir. Bu çalışmada, yoğun bakımda kolistin kullanan hastaların tedavisinde, kolistinin uygulama şeklinin nefrotoksisiteye etkisini araştırmayı planladık. Materyal ve Metod: Çalışmaya, 90 hasta dahil edildi. Elli iki hastaya kolistin IV puşe (hızlı infüzyon) olarak verildi. Otuz sekiz hastaya yavaş infüzyonla kolistin verildi. Hastaların demografik özellikleri ve kolistin sonrası akut böbrek yetmezliği (ABY) parametreleri değerlendirilerek kaydedildi. Bulgular: Her iki grubun, hastalık özellikleri ve yaşları benzerdi. Kolistin yavaş infüzyon verilen grupta, ABY daha az gelişti (p< 0.011). Sonuç: Çok ilaca dirençli mikroorganizmalarla infekte hastaların tedavisinde kolistinin nefrotoksisite yan etkisinden kaçınmak için, uygulamanın uzun infüzyon şeklinde yapılması etkili bulunmuştur. Bu konu, ileri çalışmalarla desteklenmelidir.

🔖

Cite This Article

HABİLOĞLU, A. D., YAPAR-TOROS, G., AŞKIN, T., TUNÇEL, Y. İ., DUYGU, F., ÜNVER, S., ERTEK, M. (2019). The Effect of Infusion Speed on Nephrotoxicity in Patients Receiving Colistine Treatment in Oncology Hospital. Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi, Cilt: 24 - Sayı: 2, 87–92. https://ajindex.com/articles/161040

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Levin AS, Barone AA, Penço J, Santos MV, Marinho IS, Arruda EA, et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999;28:1008-11.
  2. Wallaces J, Li J, Rayner CR, Coulthard K, Nation RL. Stability of colistin methanesulfonate in pharmaceutical products and solutions for administration to patients. Antimicrob Agents Chemother 2008;52:3047-51.
  3. Yapa SWS, Li J, Porter CHJ, Nation RL, Patel K, Mcintosh MP. Population pharmacokinetics of colistin methanesulfonate in rats: achieving sustained lung concentrations of colistin for targeting respiratory infections. Antimicrob Agents Chemother 2013;57:5087-95.
  4. Sümer Ş, Dikici N. Kolistin. Yoğun Bakım Dergisi 2010;9:182-7. Mert A. Kolistin toksisitesi. ANKEM Derg 2012;26:22-6. www.kocakfarma.com. Erişim tarihi: 3 Ekim 2018. Available from: http://kocakfarma.com/urun-aciklama.aspx?bolumSeo=kisabilgi&id=43&lang=tr.
  5. Lopes JA, Jarge S. The RIFLE and AKIN classifications for acute kidney injury: A critical and comprehensive review. Clin Kidney J 2013;6:8-14. Aktaş F. Tedavisi güç infeksiyonlarda antibiyotiklerin farmakokinetik/farmakodinamik özelliklerinin önemi: Endokardit. ANKEM Derg 2011;25:201-6. Akalın H. Antimikrobiyal direnç ve önleme politikaları. ANKEM Derg 2011;25:190-5. Coşgun B. Dirençli gram-negatif bakteri infeksiyonlarında kolistin uygulamasının sonuçlarının değerlendirilmesi (tez). Ankara: Ankara Üniversitesi Tıp Fakültesi; 2015.
  6. Li J, Coulthard K, Milne R, Nation RL, Conway S, Peckham D, et al. Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis. J Antimicrob Chemother 2003;52:987-92.
  7. Plachouras D, Karvanen M, Friberg LE, Papadomichelakis E, Antoniadou A, Tsangaris I, et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother 2009;53:3430-6.
  8. Mohamed AF, Karaiskos İ, Plachouras D, Karvanen M, Pontikis K, Jansson B, et al. Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill. Antimicrob Agents Chemother 2012;56:4241-9.
  9. Spapen H, Jacobs R, Gorpv VV, Troubleyn J, Honoré PM. Renal and neurological side effects of colistin in critically ill patients. Ann Intensive Care 2011;1:14. H